article Open AccessTop 1% cited
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
The Lancet Oncology · 2019 · Vol. 21(2) · pp. 271–282
Robert C. Doebele(University of Colorado Anschutz Medical Campus)Alexander Drilon(Cornell University)Luis Paz‐Ares(Hospital Universitario 12 De Octubre)Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)Alice T. Shaw(Massachusetts General Hospital)Anna F. Farago(Massachusetts General Hospital)Collin M. Blakely(University of California, San Francisco)Takashi Seto(National Hospital Organization Kyushu Cancer Center)Byoung Chul Cho(Yonsei University)Diégo Tosi(Institut de Recherche en Cancérologie de Montpellier)Benjamin Besse(Institut Gustave Roussy)Sant P. Chawla(Sarcoma Oncology Center)Lyudmila Bazhenova(University of California, San Diego)John C. Krauss(University of Michigan–Ann Arbor)Young Kwang Chae(Northwestern University)Minal Barve(Mary Crowley Cancer Research Center)Ignacio Garrido‐Laguna(University of Utah)Stephen V. Liu(Georgetown University Medical Center)Paul Conkling(Virginia Oncology Associates)Thomas John(Olivia Newton-John Cancer Wellness & Research Centre)Marwan Fakih(City of Hope)Darren Sigal(Scripps MD Anderson Cancer Center)Herbert H. Loong(Chinese University of Hong Kong)Gary L. Buchschacher(Los Angeles Medical Center)Pilar Garrido(Instituto Cajal)Jorge J. Nieva(University of Southern California)Conor Steuer(Emory University)Tobias R. Overbeck(University of Göttingen)Daniel W. Bowles(University of Colorado Anschutz Medical Campus)Elizabeth Fox(Children's Hospital of Philadelphia)Todd RiehlEdna Chow‐Maneval(Ignyta (United States))Brian SimmonsNa CuiAnn Johnson(Ignyta (United States))Susan EngTimothy R. WilsonGeorge D. Demetri✉(Dana-Farber Cancer Institute)
Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanismsTrk receptorMedicineInternal medicineOncologyPopulationClinical trialCancerPhases of clinical researchResponse Evaluation Criteria in Solid TumorsReceptor
MeSH terms
AgedAntineoplastic AgentsBenzamidesFemaleHumansIndazolesMaleMembrane GlycoproteinsMiddle AgedNeoplasm MetastasisNeoplasmsTime FactorsBiomarkers, TumorTreatment OutcomeClinical Trials, Phase I as Topic
Citations
1,690
FWCI
133.75
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
Cited by
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Annals of Oncology · 2021 · 909 citations
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Annals of Oncology · 2020 · 1,151 citations
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 1,598 citations
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2022 · 1,496 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.